Sign in

    Ahanse Fu • Jefferies

    Hangfei Fu is a Biotech Equity Research Senior Associate at Jefferies, specializing in research coverage within the biotechnology sector. Drawing on deep financial analysis skills, Fu focuses on evaluating companies in the biotech industry, providing investment insights and recommendations to clients. With a career anchored at Jefferies, Fu has developed a strong analytical foundation, though no public information is available regarding specific company coverage, success rates, performance metrics, or prior employment. Professional credentials and securities licenses have not been disclosed in public records.

    Ahanse Fu's questions to Autolus Therapeutics PLC (AUTL) leadership

    Ahanse Fu's questions to Autolus Therapeutics PLC (AUTL) leadership • Q3 2024

    Question

    Ahanse Fu, on behalf of Kelly Shi, asked about physician feedback on obe-cel versus Tecartus and its potential impact on the launch. They also requested more details on the upcoming SLE data release, including patient numbers and dose levels.

    Answer

    CEO Christian Itin reported very positive physician feedback, highlighting an appreciation for obe-cel's differentiated safety profile, which is easier to manage. For the SLE trial, he stated it aims to confirm a 50 million cell fixed dose in an initial cohort of 6 patients. Initial data in Q1 will cover early activity, with longer-term follow-up data in H2 2025.

    Ask Fintool Equity Research AI